erlotinib hydrochloride has been researched along with substance p in 3 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (substance p) | Trials (substance p) | Recent Studies (post-2010) (substance p) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 17,289 | 277 | 2,010 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | substance p (IC50) |
|---|---|---|---|
| Substance-P receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Substance-K receptor | Rattus norvegicus (Norway rat) | 0.2 | |
| Substance-K receptor | Homo sapiens (human) | 0.2455 | |
| Substance-P receptor | Homo sapiens (human) | 0.0011 | |
| Neuromedin-K receptor | Homo sapiens (human) | 0.125 | |
| Substance-K receptor | Mesocricetus auratus (golden hamster) | 0.148 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buhren, BA; Gerber, PA; Homey, B | 1 |
| Chmielinska, JJ; Kramer, JH; Mak, IT; Spurney, CF; Weglicki, WB | 1 |
| Ding, D; Hu, JL; Liu, XP; Ren, H; Wang, JG; Yang, WL; Yu, J; Zhang, L | 1 |
3 other study(ies) available for erlotinib hydrochloride and substance p
| Article | Year |
|---|---|
More on aprepitant for erlotinib-induced pruritus.
Topics: Antiemetics; Aprepitant; Erlotinib Hydrochloride; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Off-Label Use; Protein Kinase Inhibitors; Pruritus; Quinazolines; Substance P | 2011 |
EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockade.
Topics: Animals; Aprepitant; Echocardiography; ErbB Receptors; Erlotinib Hydrochloride; Magnesium; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Oxidative Stress; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-1; Substance P; Ventricular Function, Left | 2015 |
Neurokinin-1 activation affects EGFR related signal transduction in triple negative breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptors, Neurokinin-1; RNA Interference; RNA, Small Interfering; Signal Transduction; Substance P; Triple Negative Breast Neoplasms | 2015 |